MYCBP and primary cutaneous T-cell non-Hodgkin lymphoma: In these studies, miR-22 was determined to have many effects such as inhibition of: cyclin dependent kinase 2 (CDK2), histone deacetylase 6 (HDAC6), MYC associated factor X (MAX), MYC binding protein (MYCBP), nuclear receptor coactivator 1 (NCOA1), and PTEN. These genes have previously been implicated in cutaneous T-cell lymphoma (CTCL) [156].